<DOC>
	<DOCNO>NCT02222376</DOCNO>
	<brief_summary>Pirfenidone synthetic molecule , act potent modulator effect various cytokine ( TNF-α , transform growth factor-β , platelet derive growth factor vascular endothelial growth factor , among others ) possess anti-inflammatory anti-fibrinolytic property . The aim study compare effect topic treatment pirfenidone compare conventional treatment chronic diabetic foot ulcer . The hypothesis treatment topic pirfenidone chronic diabetic foot ulcer ( Wagner 1 2 ) reduces ulcer size shortens heal time compare conventional treatment . This randomize , control crossover study . Patients randomly assign conventional treatment topic pirfenidone eight week . At end period change group . Each week ulcer size , depth , length evidence infection . The ulcer proper debridement conventional treatment group debridement plus topical pirfenidone application pirfenidone group . Subjects instructed daily ulcer cleanse topical pirfenidone group , addition cleansing instruct apply gel twice day .</brief_summary>
	<brief_title>Effect Topic Pirfenidone Diabetic Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>1 . Men woman 2 . Type 1 2 diabetes 3 . Age ≥ 18 year 4 . Wagner 1 2 diabetic foot ulcer 5 . Diabetic ulcer 8 week duration 6 . Willing participate study sign informed consent 1 . Ankle/brachial index &lt; 0.4 ( critic ischemia ) 2 . Use topical systemic antibiotic 3 . Inability attend weekly evaluation 4 . Inability daily ulcer cleanse 5 . Autoimmune diseases 6 . Active pharmacologic topical systemic ulcer treatment 7 . Treatment immunosuppressor steroid , radiotherapy , chemotherapy 8 . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Diabetic ulcer , diabetic foot</keyword>
</DOC>